{"id":"mspv4","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain/erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MSPV4 is a multivalent meningococcal conjugate vaccine designed to provide protection against four major disease-causing serogroups of Neisseria meningitidis (B, C, W, and Y). The vaccine works by presenting bacterial polysaccharide antigens conjugated to a carrier protein, which enhances T-cell dependent immune responses and generates both antibody and cellular immunity against these serogroups.","oneSentence":"MSPV4 is a recombinant meningococcal serogroup B, C, W, and Y conjugate vaccine that stimulates immune responses against multiple meningococcal serogroups.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:49:45.567Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of meningococcal disease caused by Neisseria meningitidis serogroups B, C, W, and Y"}]},"trialDetails":[{"nctId":"NCT06226714","phase":"PHASE3","title":"A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-01","conditions":"Meningococcal Meningitis","enrollment":840},{"nctId":"NCT06011200","phase":"PHASE3","title":"A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-09-16","conditions":"Epidemic Meningitis","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MSPV4","genericName":"MSPV4","companyName":"CanSino Biologics Inc.","companyId":"cansino-biologics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"MSPV4 is a recombinant meningococcal serogroup B, C, W, and Y conjugate vaccine that stimulates immune responses against multiple meningococcal serogroups. Used for Prevention of meningococcal disease caused by Neisseria meningitidis serogroups B, C, W, and Y.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}